African Journal of
Medicine, Surgery and Public Health Research

ISSN: 1595-8000

Index: Harvard, Boston, Sydney University, Dimensions, Lens, ResearchGet Scilit, Semantic, Google Scholar, Base etc

https://doi.org/10.58578/AJMSPHR.v2i2.5580

Understanding Gastritis: Causes, Symptoms, Diagnosis, and Management

Muhammad Akram[1], Abid Mahmood[2], Isaac John Umaru[3], Mohammed Khudhair Hasan[4], Hind A. Abdulghafoor[5], Fahad Said Khan[6], Fethi Ahmet Ozdemir[7], Gaweł Sołowski[8], Jaouher Ben Ali[9], Jehan Mohammad Al-Musawi[10]

[1,2]Government College University Faisalabad, Pakistan; [3] Federal University Wukari Taraba State, Nigeria; [4]Al Manara College for Medical Sciences, Maysan, Iraq; [5]University of Fallujah, Iraq; [6]University of Poonch Rawalakot, Azad Jammu and Kashmir, Pakistan; [7,8]Bingol University, Bingol, Türkiye; [9]University of Tunis, Tunisia; [10]University of Kufa, Najaf Iraq

makram_0451@yahoo.com

Article Info:

Submitted:	Revised:	Accepted:	Published:
Mar 30, 2025	Apr 14, 2025	Apr 26, 2025	May 1, 2025

Abstract

One such common disorder is gastritis, that is bound to cause acute or chronic inflammation of the stomach lining. It is primarily caused due to the long duration use of NSAIDs, Helicobacter pylori infection or many other reasons. Alcohol consumption, stress, bile reflux and some immunological processes also play a role in causing gastritis. While some relatives remain asymptomatic, most relatives experience symptoms such as epigastric discomfort, vomiting, and, in some cases, gastrointestinal bleeding. H. Pylori detection, endoscopic examination, and histopathology are the primary techniques for diagnosing gastritis. Another method of treatment is the use of proton pump inhibitors along with lifestyle changes, or antibiotics. Gastritis and its symptoms can be mitigated by employing primary prevention strategies like proactively treating H. Pylori infections or reducing NSAIDs consumption.

Keywords: Autoimmune gastritis, Helicobacter pylori, Proton pump inhibitors, NSAIDs, Goblet cell metaplasia, Stomach inflammation, Upper endoscopy

Introduction

Gastritis, a word that denotes the inflammation of the stomach mucosa, is a health concern across the globe due to its high prevalence (Appelman et al 1994). The acute and chronic forms of gastritis will appear depending on the underlying factors and the person's general state of health. Acute gastritis should resolve within a few days when adequate care is provided. Chronic gastritis on the other hand, can progress insidiously causing atrophy and metaplasia, thus leading to, at times, irreversible damage to the stomach lining. This syndrome is often associated with distal social factors including infections, stress mismanagement, unhealthy food and alcohol intake, as well as ef ISN forms of medication (Dhurjati et al 2020). For chronic sufferers of stomach ulcers or cancer, understanding the aetiology, risk factors, clinical manifestations, and therapeutic options available is critical for timely and accurate intervention.

Causes and Risk Factors

Both infectious and non-infectious aspects contribute to the complex aetiology of gastritis. One of the primary infectious causes is the gram-negative bacterium Helicobacter pylori, which erodes the stomach mucosa. The acid produced damages the tissue located behind the mucosal barrier, further aggravating and perpetuating the inflammation (acute gastritis). Chronic infection with this bacterium is linked to the development of serious illness such as stomach cancer, MALT lymphoma, and peptic ulcers (Parsonnet et al 2004). NSAIDs are also a significant factor due to long term use. They diminish the protective qualities of the stomach by reducing blood supply to the mucosal layer, through inhibition of prostaglandin synthesis, and increasing vulnerability to acid. In addition, eroding and irritating the stomach lining may be caused by excessive alcohol intake, while damage by cigarette smoking is multifaceted: it inhibits healing and promotes damage, and accelerates the development of gastric cancer tissue. Auto-immune gastritis, a rare, but life-threatening condition is caused by an immune attack on parietal stomach cells; it impairs intrinsic

factor synthesis, disrupting vitamin B12 metabolism. Inflammation is more common among hospitalised patients and can further fuel psychological stressors and physical insults such as burns, sepsis, or trauma (Varela et al 2018).

Clinical Presentation

Gastritis may produce a variety of symptoms such as pain and discomfort, bleeding, and vestibular symptoms. Most cases are asymptomatic and are discovered incidentally during an unrelated endoscopic procedure, particularly in cases of chronic gastritis. Nausea, vomiting, bloating, appetite suppression, and epigastric discomfort—or searing gnawing pain within the stomach region together with early satiety—are some of the more commonly reported complaints when symptoms are mild. Worsening symptoms are more likely to occur with consumption of food, especially if it is acidic, greasy, or spicy (Wytiaz et al 2015). More serious symptoms such as persistent anemia, melena, and haemorrhage may arise if there is coexisting ulceration or erosion of blood vessels diagnosis_a6037 coexisting in inflammation. Other neurological symptoms that may be included in autoimmune gastritis are peripheral neuropathy, lethargy, and amnesia due to spinal B12 deficiency. The symptoms are too generic to allow distinction between GERD and other conditions, thus requiring further investigation.

Diagnosis

A diagnosis of gastritis can be done accurately with the help of a clinical diagnosis followed by laboratory testing and endoscopic procedures (Carpenter et al 1995). During an upper GI endoscopy, the physician examines the mucosa of the stomach to identify any signs of gastritis which may include erosion, hemorrhage, atrophy, and erythema. In addition to visual assessment, several biopsy specimens are taken for H. pylori infection, inflammation, and to rule out malignancy. Non-invasive H. pylori confirmation can also be done using a stool antigen test, a serological test, or the more specific urea breath test. Further blood analyses may reveal the presence of anemia along with iron and vitamin B12 deficiency which is typical in chronic or autoimmune gastritis. It is important to take a comprehensive drug history for patients suspected to have NSAID associated gastritis. Ultrasound and CT scans of the abdomen are not primary diagnostic tools for gastritis but may be used to assess its effects (Xue et al 2017).

Treatment and Management

The treatment regimen is tailored according to the underlying pathology of gastritis. In patients with H. pylori, typically a triple or quadruple therapy is prescribed where clarithromycin with either amoxicillin or metronidazole and a PPI is administered for 10-14 days. For NSAID induced gastritis, the cause is eliminated, the offending agent is stopped, and a PPI is started to allow the epithelium and mucosa to heal (Mason et al 2001). Milder presentations may benefit from the use of antacids. Symptomatic relief can be provided by H2 receptor antagonists. Long term treatment for autoimmune gastritis is with peripheral B12 and active surveillance for other complications such as gastric tumours from atrophy or severe underlying pernicious anaemia. Flares of any type of gastritis can be averted with modifications in lifestyle. Managing stress, having a well-balanced diet, and avoiding tobacco, alcohol, and spicy foods make positive contributions. Regular screening and surveillance are essential for everyone, but patients with atrophic or chronic gastritis require them more frequently as they are at a greater risk of more serious disorders including peptic ulcer disease and stomach cancer (Sipponen et al 1993).

Prevention

Public health campaigns, personal decisions, and treatments are the three main methods for preventing gastritis. Promoting alternate pain management treatment methods along with public education on the consequences of NSAID gastritis can mitigate drug-induced gastritis. In developing regions where H. pylori is endemic, improved hygienic conditions and the promotion of proper hygiene will help curb the transmission of this pathogen. Aggressive screening and treatment of H. pylori infections in at-risk patients may reduce the incidence of gastritis and its complications, such as peptic ulcers and gastric cancer, in identified patients (O'connor et al 2017). Known susceptible patients must undertake healthy dietary protocols and use adaptive psychosocial stress management techniques. High suspicion index should be the approach for clinicians in diagnosing and treating gastritis for patients who are already showing symptoms early on.

Conclusion

Like other gastrointestinal disorders, gastritis has clinical consequences that need to be managed and closely watched. It could manifest as a little ailment like dyspepsia or as a

more serious condition like bleeding or cancer. Accurately diagnosing gastritis and determining its causes of development is essential because it is a complex, multifaceted disorder. Treatment philosophies differ depending on the underlying reason, but the mainstays of therapy include drug removal, acid suppression, and treatment of H. pylori infection. Prudent use of medication marketing and responsible public education initiatives are needed to lessen the incidence. The majority of cases are manageable with the right steps done at the right times, which will unavoidably improve patient outcomes, such as their quality of life and course of recovery.

References

Appelman, H. D. (1994). Gastritis: Terminology, Etiology, and Clinicopathological Correlations: Another Biased View. Human Pathology, 25(10), 1006-1019.

Carpenter, H. A., & Talley, N. J. (1995). Gastroscopy Is Incomplete Without Biopsy: Clinical Relevance of Distinguishing Gastropathy from Gastritis. Gastroenterology, 108(3), 917-924.

Dhurjati, R. (2020). Abstracts for ANCIPS 2020. Indian Journal of Psychiatry, 62(Suppl 1), S30-S73.

Mason, J. C. (2001). NSAID Related Upper Gastrointestinal Damage, Prevalence and Pathogenesis, with Particular Reference to the Role of Epidermal Growth Factor. The University of Manchester. [Missing

O'Connor, A., O'Morain, C. A., & Ford, A. C. (2017). Population Screening and Treatment of Helicobacter Pylori Infection. Nature Reviews Gastroenterology & Hepatology, 14(4), 230-240.

Parsonnet, J., & Isaacson, P. G. (2004). Bacterial Infection and MALT Lymphoma. The New England Journal of Medicine, 350, 213-215.

Sipponen, P., & Hyvärinen, H. (1993). Role of Helicobacter Pylori in the Pathogenesis of Gastritis, Peptic Ulcer and Gastric Cancer. Scandinavian Journal of Gastroenterology, 28(Sup196), 3-6.

Varela, M. L., Mogildea, M., Moreno, I., & Lopes, A. (2018). Acute Inflammation and Metabolism. Inflammation, 41, 1115-1127.

Wytiaz, V., Homko, C., Duffy, F., Schey, R., & Parkman, H. P. (2015). Foods Provoking and Alleviating Symptoms in Gastroparesis: Patient Experiences. Digestive Diseases and Sciences, 60, 1052-1058.

Xue, H., Ge, H. Y., Miao, L. Y., Wang, S. M., Zhao, B., Wang, J. R., & Cui, L. G. (2017). Differential Diagnosis of Gastric Cancer and Gastritis: The Role of Contrast-Enhanced Ultrasound (CEUS). Abdominal Radiology, 42, 802-809.